Reuters (2/8, Sunny) reports that a high-dose version of Hikma Pharmaceuticals’ opioid reversal spray, naloxone, did not improve survival rates compared to lower-dose offerings when administered by New York law enforcement in emergencies, a recent U.S. study finds. The study also indicated that the higher-dose spray led to a greater risk of opioid withdrawal symptoms. The spray was approved in 2021 to counteract potent opioids like fentanyl. The findings were published in the CDC’s Morbidity and Mortality Weekly Report.
The AP (2/8, Stobbe ) reports, “The 8-milligram naloxone spray – twice as potent as the highest dose previously available – was approved two years ago after pressure from experts and patient advocates who noted lower-dose antidotes often were being given multiple times to people suffering overdoses.”
Related Links:
— “High-dose opioid reversal spray no better than lower dose in field, US study finds,”Mariam Sunny, Reuters, February 8, 2024